 |
|
|
| |
FINAL RESULTS OF THE PYRAMID 1 STUDY, A PHASE 3 REGISTRATIONAL TRIAL OF RAVIDASVIR (PPI-668) AND SOFOSBUVIR IN HCV GENOTYPE-4 PATIENTS: HIGH RATES OF SUSTAINED VIRAL CLEARANCE IN CIRRHOTIC AND NON-CIRRHOTIC PATIENTS
|
| |
| |
Reported by Jules Levin
EASL 2016 April 14-17 Barcelona
Gamal Esmat* 1, Maissa El Raziky1, 2, Asmaa Gomaa3, Tamer Elbaz1, Mahmoud Abouelkhair1, 2, Alyaa Sabry3, Hadeel Gamel El Deen1, Mohamed Ashour1, 2, Mohammed Abdel-Hamid4, Ola Nada5, Sherine Helmy6, Hanaa Abdel-Maguid6, Richard Colonno7, Nathaniel Brown7, Eric Ruby7, Pamela Vig8, Imam Waked3
1Cairo University, 2Cairo Fatemic Hospoital, 3National Liver Institute, 4Minia University, 5Ain Shams University, Cairo, 6Pharco Pharmaceuticals, Alexandria, Egypt, 7Presidio Pharmaceuticals, San Francisco, United States, 8Presidio Pharmaceuticals, San Francisco, Egypt
|
| |
|
|
|
|
|
